Navigation Links
Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2011 Financial Results and Provides Pipeline Update
Date:11/2/2011

">($0.39)($0.65)Shares used in calculation of basic and diluted net loss per share:  

96,13372,93487,41469,941(1) Share-based compensation expenses included in operating
expenses amounted to approximately:Research and development

$
269$
308$
820$
942General and administrative

3456461,0231,950IDENIX PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(IN THOUSANDS)(UNAUDITED)September 30,

2011

December 31,

2010ASSETSReceivables from related party

$ 64,693

$ 46,115Cash and cash equivalents

1,161

840Other current assets

3,845

2,535Total current assets

69,699

49,490Intangible asset, net

8,992

9,843Property and equipment, net

5,647

7,179Other assets4,451

3,372Total assets

$   88,789

$   69,884LIABILITIES AND STOCKHOLDERS' DEFICITAccounts payable and accrued expenses

$ 8,952

$ 14,030Deferred revenue, related party

3,040

3,036Other current liabilities

3,104

2,928Total current liabilities

15,096

19,994Other long-term obligations

49,659

52,398Deferred revenue, related party, net of current portion

26,343

28,588Total liabilities

91,098

100,980Stockholders' deficit

(2,309)

(31,096)Total liabilities and stockholders' deficit

'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
2. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
3. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
4. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
5. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
6. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
7. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
8. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
9. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2009 Financial Results
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Idenix Announces Data Presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... MARLBOROUGH, Mass. , March 27, 2015 ... ) and privately-held MirImmune LLC, today announced ... license agreement to RXi,s novel and proprietary ... cell-based cancer immunotherapies. The collaboration has the ... and patient friendly cancer treatments that could ...
(Date:3/27/2015)... RnRMarketResearch.com adds "Visceral Pain ... report of 52 pages with latest updates, data ... The report "Visceral Pain - Pipeline Review, H1 ... for Visceral Pain, complete with comparative analysis at ... of action (MoA), route of administration (RoA) and ...
(Date:3/27/2015)... Concord Medical Services Holdings Limited ("Concord ... a leading specialty hospital management solution provider and ... diagnostic imaging centers in China ... agreement under which Concord Medical Services (International) Pte ... agreed to acquire the Fortis Surgical Hospital from ...
Breaking Medicine Technology:RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 2Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 3
... 25, 2012 Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... quarter 2012 financial results after the Nasdaq market closes on ... conference call and webcast to discuss its financial results and ... 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). ...
... 25, 2012 STAAR Surgical Company (NASDAQ: STAA ) today ... ended March 30, 2012 on Wednesday, May 2, 2012 ... a conference call and webcast on Wednesday, May 2, 2012 ... to discuss the Company,s first quarter 2012 results and recent ...
Cached Medicine Technology:STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast 2
(Date:3/28/2015)... Delaying rotator cuff surgery on patients with ... presented today at the American Orthopaedic Society for Sports ... compared results for 170 patients who received rotator cuff ... capsule release procedure to relieve stiffness at the time ... from St. George Hospital in Sydney, Australia. “Both groups ...
(Date:3/28/2015)... NC (PRWEB) March 28, 2015 Genomic ... with peritoneal mesothelioma, revealing, for the first time, key ... Click here to read the newly posted story ... at the University of British Columbia, the British Columbia ... genome mapping to reveal underlying molecular alterations and mutations ...
(Date:3/28/2015)... Lately the student-athlete experience ... and proposals around the NCAA. In a March episode ... student-athletes across a spectrum of universities and sports shed ... The special panel consists of athletes who have competed ... football, track and field, baseball, and volleyball. They discuss ...
(Date:3/28/2015)... Mirada, CA (PRWEB) March 28, 2015 ... ear, nose and throat disorders, are now ... is a common issue which is characterized by the ... Affecting 1 in 5 people, tinnitus is a prevalent ... disorder and while it is non-fatal, tinnitus can impede ...
(Date:3/28/2015)... Designers and Professionals of FCPX plugins ... from Pixel Film Studios. , “Scratches 5K allows users ... Final Cut Pro X” Said Christina Austin, CEO of ... an effective tool for any FCPX editor.” , Scratch ... grunge overlays. Simply drag title layers into the FCPX ...
Breaking Medicine News(10 mins):Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 3Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2Health News:Pixel Film Studios Unveiled Scratches 5k for Final Cut Pro X Editors 2
... in the Sun Volunteers Mount Winning Effort to Fight Skin Cancer, ... ... Creamer Triumphs, HALF MOON BAY, Calif., Oct. 17 ... up at the recent LPGA,s Samsung,World Championship in Half Moon Bay, CA ...
... centuries civilizations have,flocked to warm bubbly waters to soothe ... high tech home spas of today that can cost,anywhere ... economic uncertainty,is a backyard water oasis simply a luxury ... science behind the soak?, To view the Multimedia ...
... identify those most at risk from hair loss is now available in ... ... 17, 2008 -- A groundbreaking genetic test to identify those most at ... men and women. , , ,Currently only available at Farjo Hair ...
... to Combat Blindness, LISBON, Portugal and NEW ... the largest global science foundations, invites all,institutions working ... for the,Antonio Champalimaud Vision Award. The Award is ... of blindness and,visual impairment. The prestigious Award, which ...
... Americans United for Life,(AUL) today filed an amicus ... of the deadly abortion drug, RU-486., AUL President ... of ruining and even ending women,s lives. We must ... drug. Ohio,s statute is a,step in the right direction, ...
... fixed incomes are particularly challenged by rising expenses, including housing, healthcare ... ... Belleville, Ill. (Vocus) October 16, 2008 -- For the more than ... awaiting a decision on their application for benefits, the 5.8 percent ...
Cached Medicine News:Health News:Sun Safety Champions Team Up With LPGA Tour Pro Paula Creamer 2Health News:Sun Safety Champions Team Up With LPGA Tour Pro Paula Creamer 3Health News:Sun Safety Champions Team Up With LPGA Tour Pro Paula Creamer 4Health News:Video: The Science Behind the Soak - a Coping Tool for Today's Changing World 2Health News:Breakthrough Baldness Genetic Test 2Health News:The Champalimaud Foundation Invites Nominations and Applications for Its 2009 Vision Award 2Health News:The Champalimaud Foundation Invites Nominations and Applications for Its 2009 Vision Award 3Health News:Ohio's Regulation of RU-486 Clear and Constitutional, Should Be Upheld Argues AUL in Brief Filed Before Ohio Supreme Court 2Health News:Social Security 2009 COLA Helps, But People with Disabilities Will Still Struggle, Says Allsup 2Health News:Social Security 2009 COLA Helps, But People with Disabilities Will Still Struggle, Says Allsup 3Health News:Social Security 2009 COLA Helps, But People with Disabilities Will Still Struggle, Says Allsup 4Health News:Social Security 2009 COLA Helps, But People with Disabilities Will Still Struggle, Says Allsup 5Health News:Social Security 2009 COLA Helps, But People with Disabilities Will Still Struggle, Says Allsup 6Health News:Social Security 2009 COLA Helps, But People with Disabilities Will Still Struggle, Says Allsup 7
... Reposable system components for creating each access port are ... is packaged sterile together with either a 5 mm ... needle is packaged non-sterile; 5 mm, 7/8 mm, ... 5 mm, 7/8 mm, 10 mm and 12 ...
VERSAPORT™ Plus RT Single Use Obturators for use with VERSAPORT™ RT Reusable Cannulae....
The SURGINEEDLE™ is a veress type needle that is used to insufflate the abdomen to create pneumoperitoneum....
... complete line of Surgical Access ...unlike any ... OnePort™ trocar system is actually four systems ... operationally flexible and clinically adaptive to all ... in disposability and bladed or dilating tip ...
Medicine Products: